<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849236</url>
  </required_header>
  <id_info>
    <org_study_id>2015_17</org_study_id>
    <secondary_id>2016-000157-12</secondary_id>
    <nct_id>NCT02849236</nct_id>
  </id_info>
  <brief_title>PECS I Block for Breast Subpectoral Implant Surgery</brief_title>
  <official_title>Analgesic Efficacy of the Pectoral Nerve Block Type 1 for Breast Subpectoral Implant Surgery: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast augmentation surgery can cause important postoperative pain, especially when bilateral&#xD;
      subpectoral implants are used. The investigators hypothesized that a technique of regional&#xD;
      analgesia, the pectoral nerve block type I (or &quot;PECS I block&quot;) would reduce pain within the&#xD;
      first twenty-four hours and, in turn, morphine consumption and associated side effects. This&#xD;
      is a randomized, controlled, double-blind study which compares intra and postoperative&#xD;
      analgesia with or without PECS I block in breast surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2016</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption</measure>
    <time_frame>During the first 24 postoperative hours</time_frame>
    <description>Morphine consumption by use of patient control analgesia within the first twenty-four hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First administration of morphine</measure>
    <time_frame>During the first 24 postoperative hours</time_frame>
    <description>Time elapsed between tracheal extubation and first administration of morphine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative nausea and/or vomiting</measure>
    <time_frame>During the first 24 postoperative hours</time_frame>
    <description>Number of nausea and/or vomiting episodes in the twenty-four hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative opioids consumption</measure>
    <time_frame>During procedure execution</time_frame>
    <description>Sufentanil consumption during anesthesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative anti-emetic consumption</measure>
    <time_frame>During the first 24 postoperative hours</time_frame>
    <description>Consumption of anti-emetic drugs after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>During the first 24 postoperative hours</time_frame>
    <description>Evaluation of post-operative pain with a digital scale from 0 to 10 in the first twenty four hours after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-point sedation scale</measure>
    <time_frame>During the first two postoperative hours</time_frame>
    <description>using WHO Sedation scale&#xD;
- 0 = awake and alert /- 1 = quietly awake / - 2 = asleep but easily roused / - 3 = deep sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldrete score</measure>
    <time_frame>During the first two postoperative hours</time_frame>
    <description>Aldrete Score is a medical scoring system for the measurement of recovery after anesthesia (post anesthesia) which includes activity, respiration, consciousness, blood circulation and color.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time physiological function recovery</measure>
    <time_frame>During the first six postoperative hours after tracheal extubation</time_frame>
    <description>Ability to drink, to eat, to urinate, to walk</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PECS block performed with Saline solution instead of local anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PECS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PECS block performed with Ropivacaine 3.75mg/mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (PECS bloc)</intervention_name>
    <description>Ropivacaine 3.75mg/mL&#xD;
Injection of a local anesthetic between pectoral major and pectoral minor muscles</description>
    <arm_group_label>PECS group</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>20 mL saline 0.9%</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Every female who will benefit of a bilateral subpectoral breast augmentation&#xD;
&#xD;
          -  Age more than 18 years&#xD;
&#xD;
          -  Social insured&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusal of the patient&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Inability to consent&#xD;
&#xD;
          -  History of thoracic surgery or breast implants&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to use a patient controlled analgesia&#xD;
&#xD;
          -  Contraindication of the use of opioids or local anesthetics&#xD;
&#xD;
          -  Pathology of hemostasis, infection&#xD;
&#xD;
          -  Can not use a PCA&#xD;
&#xD;
          -  Patients under long-term opioids (WHO pain ladder 2 and 3)&#xD;
&#xD;
          -  Patient presenting neuropathic pain during the preoperative period (score greater than&#xD;
             or equal to 4 to the DN4 questionnaire, or taking anti-epileptic or antidepressant&#xD;
             treatments for neuropathic pain)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Tavernier, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Roger Salengro, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PECS block,</keyword>
  <keyword>pectoral block,</keyword>
  <keyword>breast augmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

